JKphArma

Partnerships

Partnerships constitute a key element of the co-development strategy pursued by

 

JKphArma Galenic Innovation

 

which is seeking to conclude co-development and licensing contracts with pharmaceuticals companies in order to perform phase III biodisponibilité studies for the following products:

> SUB-LINGUAL PILOCARPINE :
TREATMENT OF XEROSTOMIA ASSOCIATED WITH GOUGEROT-SJÖGREN SYNDROME OR RADIOTHERAPY.

 

 Phase I dose-ranging ongoing: results expected in Octobre 2016.

 Phase I biodisponibilité scheduled for late 2016: results expected mid-2017.

 Phase III tolerance scheduled for late 2017: results expected late 2018.

 Worldwide industrial protection until 2030.

Significant commercial potential, since no similar application is currently available worldwide. Extension of indications can be developed (elderly population, Drug induced)

> STATINS: PRAVASTATINE B.P.M.®
TREATMENT OF HYPERCHOLESTEROLAEMIA AND PREVENTION OF MYOCARDIAL INFARCTION.

 

Phase I dose-ranging mid-2017 : results expected late 2017.

Phase I biodisponibilité scheduled for 2018: results expected late 2018.

Phase III tolerance scheduled in 2019: results expected in 2019.

Worldwide industrial protection until 2034.

Very significant commercial potential.

> MELATONIN VIA THE BUCCAL PER-MUCOUSROUTE (“BPM®”)
AS A DIETARY SUPPLEMENT AT 1MG/0.5ML.

 

Allowed under the EFSA rule regarding “Melatonin Dietary Supplement” (EFSA Journal 2011;9(6): 2241), this galenic form offers the only Melatonin on the market with instant circulatory bioavailability. Available for marketing, we are seeking a partner for a sub-licence.

The other products via the per-mucous gingivo-jugal route in the portfolio may also be pursued via co-development from the first phase (dose-ranging study).

Numerous lipophilic active ingredients may now be administered via the buccal per-mucous route (BPM®) thereby offering instantaneous systemic bioavailability, providing rapid efficacy at very low useful dosages.

A PROJECT, A QUESTION?

We will reply without delay.